# India Hematopoietic Stem Cell Transplantation Market > India Hematopoietic Stem Cell Transplantation Market Research Report: Size, Share, Trend Analysis By Transplant Type (Allogeneic, Autologous), By Indication (Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Other Non-Malignant Disorders) and By Applications (Bone Marrow Transplant, Peripheral Blood Stem Cells Transplant, Cord Blood Transplant) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 11.9% - **2024:** $ 196.17 Million - **2025:** $ 219.52 Million - **2035:** $ 675.86 Million - **Key Players:** Novartis (CH), Bristol-Myers Squibb (US), Amgen (US), Gilead Sciences (US), Celgene (US), Takeda Pharmaceutical (JP), Roche (CH), Merck & Co. (US), AstraZeneca (GB) **Report ID:** MRFR/LS/48284-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/india-hematopoietic-stem-cell-transplantation-market-50041 --- ## Market Summary ## **India Hematopoietic Stem Cell Transplantation Market Overview** As per MRFR analysis, the India Hematopoietic Stem Cell Transplantation Market Size was estimated at 218.94 (USD Million) in 2023. The India Hematopoietic Stem Cell Transplantation Market Industry is expected to grow from 245(USD Million) in 2024 to 653 (USD Million) by 2035. The India Hematopoietic Stem Cell Transplantation Market CAGR (growth rate) is expected to be around 9.321% during the forecast period (2025 - 2035) **Key India Hematopoietic Stem Cell Transplantation Market Trends Highlighted** The India Hematopoietic Stem Cell Transplantation Market is witnessing significant growth driven by an increase in the prevalence of hematological disorders, such as leukemia and lymphoma. The rising awareness about stem cell therapy among patients and healthcare providers is boosting demand for these treatments. Government initiatives aimed at enhancing healthcare infrastructure, including the establishment of advanced transplantation facilities and the provision of financial assistance for patients, are also contributing to market expansion.  Notably, the introduction of national policies promoting organ and tissue donation is essential, as it raises the availability of hematopoietic stem cells for transplantation procedures.In recent times, there have been several opportunities to be explored in the Indian market. The growing interest in cord blood banking presents a unique chance for healthcare providers and entrepreneurs to invest in this sector, as it may lead to better outcomes for patients undergoing transplant surgeries. Additionally, collaboration with international research institutions can help in the development of innovative stem cell therapies tailored to the Indian demographic.  The emergence of telemedicine and digital health platforms is also enhancing access to information and consultations for potential patients, leading to increased engagement in treatment options.Moreover, the focus on personalized medicine and advancements in gene editing technologies offer promising avenues in the hematopoietic stem cell transplantation realm. As India continues to strengthen its biomedical research initiatives, new techniques, and transplant methodologies are likely to emerge, significantly improving patient outcomes.  Overall, the Hematopoietic Stem Cell Transplantation Market in India is evolving rapidly, driven by a combination of increased patient awareness, government support, and technological innovations. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **India Hematopoietic Stem Cell Transplantation Market Drivers** **Increasing Cancer Incidence in India** The growing frequency of cancer is one of the major factors propelling the India Hematopoietic Stem Cell Transplantation Market Industry. The National Cancer Registry Programme of India reports that the number of cancer cases in the nation has increased alarmingly, with estimates indicating that there may be around 1.5 million new cases of cancer every year by 2025. The need for hematopoietic stem cell transplants is anticipated to increase dramatically as therapeutic alternatives become more widely available and acknowledged, given the variety of malignancies that require such treatments.  These figures, which reflect the growing need for stem cell operations, are compiled and distributed in large part by organizations such as the Tata Memorial Centre. This trend points to a growing market for hematopoietic stem cell transplantation as the Indian government pushes for programs aimed at enhancing cancer care facilities and promoting cutting-edge therapies. **,Advancements in Technology** Technological advancements in transplant techniques and post-transplant care are also driving the growth of the India Hematopoietic Stem Cell Transplantation Market Industry. Innovations such as new cell separation technologies and improved methods for donor selection have enhanced patient outcomes. The introduction of robotic-assisted surgery and minimally invasive techniques has made stem cell procedures more efficient and manageable.  Institutions like the All India Institute of Medical Sciences (AIIMS) have been at the forefront of this technological revolution, contributing to research and development in the field.Such improvements not only lead to better recovery rates but also increase patient trust in hematopoietic stem cell transplants, thereby boosting market growth. **Rising Awareness and Acceptance of Stem Cell Therapies** The growing awareness and acceptance of hematopoietic stem cell therapies among the Indian population have significantly impacted the India Hematopoietic Stem Cell Transplantation Market Industry. Awareness campaigns led by organizations such as the Indian Society of Hematology and Blood Transfusion educate the public on the potential benefits of stem cell therapy in treating blood disorders and various cancers. Public interest in these therapies has surged, with increased attendance at informational seminars and workshops.According to a survey conducted by the healthcare foundation, approximately 40% of participants indicated a willingness to consider stem cell transplantation as a treatment option, reflecting a shift in acceptance that is likely to promote demand and growth in the market over the coming years. **India Hematopoietic Stem Cell Transplantation Market Segment Insights** **Hematopoietic Stem Cell Transplantation Market Transplant Type Insights** The India Hematopoietic Stem Cell Transplantation Market exhibits a diverse Transplant Type landscape, primarily segmented into Allogeneic and Autologous transplants. Allogeneic transplants involve the infusion of stem cells from a compatible donor, which is critical in treating numerous hematological conditions, including leukemia and lymphoma. This type is increasingly gaining prominence due to rising awareness about donor matching and advancements in tissue typing, making it a significant facet of the overall growth of the market. The demand for Allogeneic transplants is bolstered by the growing donor registries and initiatives aimed at improving patient access to suitable grafts.On the other hand, Autologous transplants rely on a patient’s stem cells, making them a safer option with fewer risks of graft-versus-host disease.  This approach is favorable for conditions like multiple myeloma and certain types of lymphomas. Autologous transplants have shown consistent growth, providing an opportunity for innovative methodologies, particularly in the collection and processing of stem cells. These two transplant types together encompass a substantial share of the India Hematopoietic Stem Cell Transplantation Market, reinforcing the market’s potential for strategic growth as healthcare infrastructure improves and the accessibility of advanced therapies increases.Through government efforts and private sector initiatives, the focus on enhancing treatment facilities has created an environment conducive to advancements in transplant technology and methodologies.  The interplay between Allogeneic and Autologous segments reflects the multifaceted approach being adopted in the field of hematopoietic stem cell transplantation, driving ongoing investment and Research and Development aimed at improving patient outcomes and broadening the scope of eligible candidates. These trends highlight the importance of the Transplant Type segments in shaping the future landscape of hematopoietic stem cell transplantation in India, positioning it as a crucial area of focus for clinicians, researchers, and investors. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Hematopoietic Stem Cell Transplantation Market Indication Insights** The India Hematopoietic Stem Cell Transplantation Market is primarily driven by the increasing incidence of hematological disorders, with various indications significantly influencing market dynamics. Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) represent critical areas due to their aggressive nature and the urgent need for effective treatment options, positioning them as key focus points for stem cell transplantation. Furthermore, both Hodgkin Lymphoma and Non-Hodgkin Lymphoma are prevalent malignancies in India, necessitating advanced therapeutic strategies and contributing to the growing demand for transplant procedures.Multiple Myeloma also plays a notable role in this segment, as advancements in treatment options improve patient outcomes and drive the need for transplantation.  Additionally, conditions categorized as Other Non-Malignant Disorders highlight the versatility of hematopoietic stem cell transplants in treating a diverse range of diseases, which creates opportunities for market growth. The increasing awareness and acceptance of such innovative treatment modalities continue to enhance the prospects for the India Hematopoietic Stem Cell Transplantation Market, driving forward strategic developments and research initiatives within the healthcare industry. **Hematopoietic Stem Cell Transplantation Market Application Insights** The Application segment of the India Hematopoietic Stem Cell Transplantation Market plays a crucial role in addressing various hematological disorders, including leukemia and lymphomas. This sector includes critical procedures such as Bone Marrow Transplant, Peripheral Blood Stem Cells Transplant, and Cord Blood Transplant. Bone Marrow Transplant is significant as it has been the most commonly used method and is often the first line of treatment for many blood-related diseases, owing to its ability to restore healthy blood cell production effectively. Peripheral Blood Stem Cells Transplant is gaining traction due to its less invasive nature and quicker recovery times compared to traditional methods, making it a preferred choice among treatment providers. Cord Blood Transplant is also increasingly important; its unique ability to provide a rich source of stem cells for transplantation has contributed to its growing acceptance in treating various conditions, especially in pediatric cases. The rising prevalence of chronic diseases and advancements in transplantation techniques are driving the demand for these applications in the country, signaling a positive trend for the India Hematopoietic Stem Cell Transplantation Market. **India Hematopoietic Stem Cell Transplantation Market Key Players and Competitive Insights** The India Hematopoietic Stem Cell Transplantation Market has been experiencing significant growth and development as advancements in medical technology and increasing awareness of stem cell treatments contribute to broader acceptance and demand within the healthcare sector. This market is characterized by a myriad of hospitals and healthcare facilities that specialize in hemopoietic stem cell transplantation, faced with the challenge of delivering high-quality, cost-effective care to a diverse patient demographic.  Continuous developments in treatment protocols, infrastructure, and research are shaping the competitive landscape, leading to an array of services aimed at treating hematological conditions. The landscape is further influenced by strategic partnerships, research collaborations, and personalizations of treatment plans that enhance patient outcomes and support the market's dynamic nature.P D Hinduja Hospital stands as a key player in the India Hematopoietic Stem Cell Transplantation Market, recognized for its robust reputation and sophisticated healthcare infrastructure. The hospital offers comprehensive services in hematology and stem cell transplantation, leveraging its highly trained medical professionals and state-of-the-art technology.  With a long history in patient care, P D Hinduja Hospital has developed a reputation for excellence and is well-regarded for its commitment to research and innovation. This institution focuses on providing personalized treatment plans tailored to individual patient needs, thus ensuring optimal outcomes. The established trust among patients and healthcare providers positions P D Hinduja Hospital as a strong competitor within the market, attracting patients from various regions of India seeking advanced treatment options.Kokilaben Dhirubhai Ambani Hospital represents another central entity in the India Hematopoietic Stem Cell Transplantation Market, offering a wide range of services, including peripheral blood stem cell transplantation, umbilical cord blood transplantation, and autologous and allogeneic transplant procedures.  Renowned for its advanced medical technology and a team of experienced specialists, the hospital maintains a strong market presence and is dedicated to delivering high-quality patient care. Kokilaben Dhirubhai Ambani Hospital also emphasizes research and development, participating in clinical trials that enhance their service offerings. In recent years, the facility has undertaken various collaborations and strategic partnerships aimed at expanding its capabilities in hematopoietic stem cell research and patient care. With a strong focus on innovation, strategic mergers, and acquisitions, Kokilaben Dhirubhai Ambani Hospital is well poised to maintain and grow its influence within this competitive market landscape in India. **Key Companies in the India Hematopoietic Stem Cell Transplantation Market Include** **India Hematopoietic Stem Cell Transplantation Market Industry Developments** The India Hematopoietic Stem Cell Transplantation Market has witnessed significant developments in recent months. In August 2023, P D Hinduja Hospital announced the successful completion of numerous stem cell transplants, enhancing its position as a leader in hematological research and clinical practices. Kokilaben Dhirubhai Ambani Hospital has expanded its facilities for hematopoietic stem cell procedures, indicating increased patient demand. Fortis Healthcare, along with Medanta and Aster DM Healthcare, reported substantial growth in the number of stem cell transplants performed in the last year, reflecting advancements in clinical techniques and patient care standards.  In terms of mergers and acquisitions, the past year saw CK Birla Hospital enter a collaboration with Tata Memorial Centre to enhance research capabilities. Moreover, in November 2022, Apollo Hospitals announced a strategic partnership with Narayana Health to share best practices and resources in stem cell treatments across their networks. As of October 2023, the market is projected to grow rapidly due to increased awareness and advancements in healthcare technologies that support better patient outcomes in hematopoietic stem cell transplantation, positioning India as a competitive player in the global market. **India Hematopoietic Stem Cell Transplantation Market Segmentation Insights** ## Market Drivers ### Growing Awareness and Education The increasing awareness and education regarding hematopoietic stem-cell-transplantation are crucial drivers for the market in India. Public health campaigns and educational programs are being implemented to inform patients and healthcare providers about the benefits and availability of stem-cell transplants. This heightened awareness is likely to lead to an increase in the number of patients seeking treatment, thereby expanding the market. In 2025, it is estimated that around 60% of the population will have access to information about stem-cell therapies, compared to just 30% in previous years. This shift indicates a growing recognition of the importance of early diagnosis and treatment of hematological disorders, which is essential for the hematopoietic stem-cell-transplantation market's growth. As more individuals become informed, the demand for these specialized treatments is expected to rise. ### Increasing Healthcare Expenditure The rising healthcare expenditure in India is a pivotal driver for the hematopoietic stem-cell-transplantation market. As the government and private sectors allocate more funds towards healthcare, the availability of advanced medical treatments, including stem-cell transplantation, is likely to improve. In 2025, healthcare spending in India is projected to reach approximately $370 billion, reflecting a growth rate of around 12% annually. This increase in funding facilitates the establishment of specialized centers and enhances the accessibility of transplantation services. Furthermore, the growing middle-class population is expected to demand better healthcare services, thereby propelling the hematopoietic stem-cell-transplantation market forward. The emphasis on improving healthcare infrastructure and services aligns with the increasing prevalence of hematological disorders, creating a conducive environment for market growth. ### Advancements in Medical Technology Technological innovations in the field of hematopoietic stem-cell-transplantation are significantly influencing the market in India. The introduction of novel techniques, such as improved cell processing and preservation methods, enhances the success rates of transplants. For instance, the use of automated cell separators and advanced cryopreservation techniques has streamlined the transplantation process, making it more efficient. In 2025, the market for medical technology in India is expected to grow by approximately 15%, indicating a robust investment in healthcare technologies. These advancements not only improve patient outcomes but also attract more healthcare professionals to specialize in this field. Consequently, the hematopoietic stem-cell-transplantation market is likely to benefit from these technological strides, as they facilitate better treatment options and increase patient trust in the procedures. ### Rising Incidence of Genetic Disorders The increasing incidence of genetic disorders in India is a critical driver for the hematopoietic stem-cell-transplantation market. Conditions such as thalassemia and sickle cell anemia are prevalent in various regions, necessitating effective treatment options. In 2025, it is estimated that approximately 1 in 1,000 individuals will be diagnosed with a hematological disorder, highlighting the urgent need for advanced therapies. The growing burden of these diseases is prompting healthcare providers to seek innovative solutions, including stem-cell transplantation. As awareness of genetic disorders rises, more patients are likely to explore transplantation as a viable treatment option. This trend indicates a potential expansion of the hematopoietic stem-cell-transplantation market, as healthcare systems adapt to meet the increasing demand for specialized care. ### Regulatory Support and Policy Initiatives Regulatory support and favorable policy initiatives play a significant role in shaping the hematopoietic stem-cell-transplantation market in India. The government has been actively promoting stem-cell research and transplantation through various policies aimed at enhancing patient access to these treatments. Initiatives such as the National Health Mission and the establishment of stem-cell banks are indicative of the government's commitment to improving healthcare services. In 2025, it is anticipated that regulatory frameworks will become more streamlined, facilitating quicker approvals for new therapies and treatments. This supportive environment is likely to encourage investments in research and development, further propelling the hematopoietic stem-cell-transplantation market. As regulations evolve, they may also enhance the safety and efficacy of transplantation procedures, thereby increasing public confidence in these medical interventions. ## Future Outlook The [Hematopoietic Stem Cell Transplantation Market](https://www.marketresearchfuture.com/reports/hematopoietic-stem-cell-transplantation-market-21548) in India is poised for growth at 11.9% CAGR from 2025 to 2035, driven by technological advancements, increasing patient awareness, and supportive government policies. **New opportunities:** - Expansion of telehealth services for pre- and post-transplant care. - Development of personalized stem cell therapies targeting specific diseases. - Investment in advanced biobanking solutions for stem cell preservation. By 2035, the market is expected to achieve substantial growth, enhancing treatment accessibility and innovation. ## Segment Insights ### By Transplant Type: Allogeneic (Largest) vs. Autologous (Fastest-Growing) In the India hematopoietic stem-cell-transplantation market, the market share is primarily dominated by the allogeneic transplant segment, which has established a significant lead due to its effectiveness in treating a variety of hematological disorders. Allogeneic transplants, utilizing stem cells from a compatible donor, are better positioned to address complex cases requiring matched donor cells, leading to higher adoption rates across treatment facilities. Conversely, autologous transplants are emerging rapidly as the fastest-growing segment, particularly favored for certain types of cancers. The increasing acceptance of autologous transplants can be attributed to advancements in medical technology, reduced complication rates, and a growing number of clinical success stories, making them an attractive option for patients preferring to use their own stem cells. Transplant Type: Allogeneic (Dominant) vs. Autologous (Emerging) The allogeneic segment remains dominant in the India hematopoietic stem-cell-transplantation market, primarily due to its established role in curative treatments for various blood cancers and disorders. Its robust infrastructure, including donor registries and advanced matching algorithms, has bolstered its presence. On the other hand, autologous transplants are rapidly emerging due to their growing appeal in treating hematologic conditions using a patient’s own stem cells. This approach minimizes rejection risks and enhances positive outcomes. With increasing investments in technology and patient awareness, the autologous segment is poised for significant growth, appealing to those desiring less invasive options with quicker recovery times. ### By Indication: Acute Myeloid Leukemia (Largest) vs. Acute Lymphoblastic Leukemia (Fastest-Growing) In the India hematopoietic stem-cell-transplantation market, the distribution of market share among different indications reveals a strong dominance of Acute Myeloid Leukemia (AML), accounting for a significant portion of the market. Following AML, other critical segments such as Non-Hodgkin Lymphoma and Multiple Myeloma also hold noteworthy shares, while Acute Lymphoblastic Leukemia (ALL) is emerging rapidly due to increasing incidences and awareness. The growth trends within this segment are largely driven by advancements in treatment methodologies and increasing patient populations diagnosed with hematological disorders. The rising adoption of stem-cell transplantation as a preferred treatment option and heightened investments in research are propelling the expansion of ALL, which is now being recognized as the fastest-growing segment due to its improving therapeutic outcomes and efficacy. Acute Myeloid Leukemia (Dominant) vs. Acute Lymphoblastic Leukemia (Emerging) The Acute Myeloid Leukemia (AML) segment is characterized by its long-standing market presence and dominance in treatment protocols, making it a preferred choice among clinicians. This segment benefits from established treatment frameworks and a well-defined patient base. In contrast, Acute Lymphoblastic Leukemia (ALL) represents an emerging segment, with its growth fueled by innovations in treatment approaches and better diagnostic measures. The increasing recognition of ALL's distinct characteristics and treatment needs has garnered attention, positioning it as a vital focal point for new therapies and investments within the India hematopoietic stem-cell-transplantation market. ### By Application: Bone Marrow Transplant (Largest) vs. Cord Blood Transplant (Fastest-Growing) In the India hematopoietic stem-cell-transplantation market, Bone Marrow Transplant holds the largest share, largely due to its established history and widespread application in treating various blood disorders. Peripheral Blood Stem Cells Transplant and Cord Blood Transplant are significant players, but their market shares are relatively smaller compared to Bone Marrow Transplant. As patient awareness increases and the efficacy of these transplants becomes more recognized, market dynamics are gradually shifting. The growth trends for the Application segment are driven by advancements in medical technology and better patient outcomes. Cord Blood Transplant is emerging as the fastest-growing segment, attributed to its advantages such as lower risk of graft-versus-host disease and availability of matched donors. The increasing prevalence of conditions requiring stem cell transplants also propels this growth, with healthcare policies increasingly supporting novel therapies. Bone Marrow Transplant (Dominant) vs. Cord Blood Transplant (Emerging) Bone Marrow Transplant remains the dominant application in the India hematopoietic stem-cell-transplantation market, known for its effectiveness in treating severe conditions such as leukemia and lymphoma. It involves extracting stem cells from the bone marrow, which are then transplanted to the patient. This method has a long track record of success, contributing to its strong position in the market. In contrast, Cord Blood Transplant is an emerging application, gaining traction for its unique benefits. It leverages stem cells collected from umbilical cord blood, which present lower chances of rejection and a reduced risk of complications. As the medical community continues to educate patients and promote the advantages of Cord Blood Transplant, its adoption is expected to rise, enhancing its market share. ## Competitive Benchmarking The hematopoietic stem-cell-transplantation market in India is characterized by a dynamic competitive landscape, driven by increasing incidences of hematological malignancies and advancements in transplant technologies. Key players such as Novartis (CH), Bristol-Myers Squibb (US), and Gilead Sciences (US) are strategically positioned to leverage their innovative therapies and extensive research capabilities. Novartis (CH) focuses on developing targeted therapies that enhance patient outcomes, while Bristol-Myers Squibb (US) emphasizes its robust pipeline of immunotherapies. Gilead Sciences (US) is actively pursuing partnerships to expand its reach in the Indian market, indicating a trend towards collaborative approaches in addressing treatment gaps. Collectively, these strategies contribute to a competitive environment that is increasingly centered on innovation and patient-centric solutions. In terms of business tactics, companies are localizing manufacturing to reduce costs and improve supply chain efficiency. This approach is particularly relevant in a market that is moderately fragmented, with several players vying for market share. The collective influence of these key players shapes the market structure, as they engage in strategic collaborations and mergers to enhance their operational capabilities and market presence. In October 2025, Novartis (CH) announced a partnership with a leading Indian healthcare provider to enhance access to its innovative therapies for hematological conditions. This collaboration is expected to streamline the distribution of novel treatments, thereby improving patient access and potentially increasing market penetration. Such strategic alliances are crucial in a market where accessibility remains a significant challenge. In September 2025, Gilead Sciences (US) launched a new clinical trial in India aimed at evaluating the efficacy of its latest CAR-T cell therapy for patients with relapsed hematological cancers. This initiative not only underscores Gilead's commitment to advancing treatment options but also highlights the growing trend of localized clinical research, which is essential for tailoring therapies to the unique needs of the Indian patient population. In August 2025, Bristol-Myers Squibb (US) expanded its manufacturing capabilities in India, focusing on the production of its leading immunotherapy products. This strategic move is indicative of the company's long-term commitment to the region and its recognition of India as a critical market for future growth. By enhancing local production, Bristol-Myers Squibb (US) aims to reduce lead times and improve supply chain reliability, which is increasingly vital in today's competitive landscape. As of November 2025, current trends in the hematopoietic stem-cell-transplantation market are heavily influenced by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances are becoming more prevalent, as companies recognize the need for collaborative efforts to navigate the complexities of the market. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize these areas will be better positioned to thrive in an increasingly competitive environment. ## Recent News & Developments The India Hematopoietic Stem Cell Transplantation Market has witnessed significant developments in recent months. In August 2023, P D Hinduja Hospital announced the successful completion of numerous stem cell transplants, enhancing its position as a leader in hematological research and clinical practices. Kokilaben Dhirubhai Ambani Hospital has expanded its facilities for hematopoietic stem cell procedures, indicating increased patient demand. Fortis Healthcare, along with Medanta and Aster DM Healthcare, reported substantial growth in the number of stem cell transplants performed in the last year, reflecting advancements in clinical techniques and patient care standards.  In terms of mergers and acquisitions, the past year saw CK Birla Hospital enter a collaboration with Tata Memorial Centre to enhance research capabilities. Moreover, in November 2022, Apollo Hospitals announced a strategic partnership with Narayana Health to share best practices and resources in stem cell treatments across their networks. As of October 2023, the market is projected to grow rapidly due to increased awareness and advancements in healthcare technologies that support better patient outcomes in hematopoietic stem cell transplantation, positioning India as a competitive player in the global market. ## Report Scope | MARKET SIZE 2024 | 196.17(USD Million) | | --- | --- | | MARKET SIZE 2025 | 219.52(USD Million) | | MARKET SIZE 2035 | 675.86(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.9% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Novartis (CH), Bristol-Myers Squibb (US), Amgen (US), Gilead Sciences (US), Celgene (US), Takeda Pharmaceutical (JP), Roche (CH), Merck & Co. (US), AstraZeneca (GB) | | Segments Covered | Transplant Type, Indication, Application | | Key Market Opportunities | Advancements in gene editing technologies enhance treatment efficacy in the hematopoietic stem-cell-transplantation market. | | Key Market Dynamics | Rising demand for hematopoietic stem-cell-transplantation driven by advancements in technology and regulatory support in India. | | Countries Covered | India | ## Frequently Asked Questions **Q: What was the market valuation of the India hematopoietic stem-cell-transplantation market in 2024?** A: The market valuation was $196.17 Million in 2024. **Q: What is the projected market valuation for the India hematopoietic stem-cell-transplantation market by 2035?** A: The projected valuation for 2035 is $675.86 Million. **Q: What is the expected CAGR for the India hematopoietic stem-cell-transplantation market during the forecast period 2025 - 2035?** A: The expected CAGR during this period is 11.9%. **Q: Which companies are considered key players in the India hematopoietic stem-cell-transplantation market?** A: Key players include Novartis, Bristol-Myers Squibb, Amgen, Gilead Sciences, Celgene, Takeda Pharmaceutical, Roche, Merck & Co., and AstraZeneca. **Q: What are the two main types of transplants in the India hematopoietic stem-cell-transplantation market?** A: The two main types of transplants are Allogeneic and Autologous. **Q: What were the market values for Allogeneic and Autologous transplants in 2024?** A: In 2024, Allogeneic transplants were valued at $78.47 Million, while Autologous transplants were valued at $117.7 Million. **Q: What are the primary indications for hematopoietic stem-cell-transplantation in India?** A: Primary indications include Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, and Other Non-Malignant Disorders. **Q: What was the market value for Acute Myeloid Leukemia in 2024?** A: The market value for Acute Myeloid Leukemia was $39.23 Million in 2024. **Q: What applications are involved in the India hematopoietic stem-cell-transplantation market?** A: Applications include Bone Marrow Transplant, Peripheral Blood Stem Cells Transplant, and Cord Blood Transplant. **Q: What were the market values for Bone Marrow Transplant and Peripheral Blood Stem Cells Transplant in 2024?** A: In 2024, Bone Marrow Transplant was valued at $60.0 Million, while Peripheral Blood Stem Cells Transplant was valued at $70.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-hematopoietic-stem-cell-transplantation-market-50041*